Research Paper Volume 15, Issue 21 pp 12588—12617
Characterization of the immune cell function landscape in head and neck squamous carcinoma to assist in prognosis prediction and immunotherapy
Figure 5. Evaluation of the ICF score in predicting HNSCC treatment responsiveness. (A) The histogram shows the drugs with significant differences of IC50 value between high- and low- risk groups (Wilcoxon test, p < 0.05). (B) Comparisons of T cell exclusion and dysfunction scores, the comprehensive TIDE score, and the MSI score between high- and low-risk groups. (C) Comparisons of the IPS values between high- and low-risk groups.